Jazz Pharmaceuticals Reports Q2 Results as Board Updates Director Compensation Framework
The Ireland-based biopharmaceutical company filed its quarterly results while amending its non-employee director compensation policy for the sixteenth time since 2013.
Governance Updates Accompany Quarterly Filing
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) filed its Form 10-Q for the quarter ended June 30, 2026, on August 3, disclosing updates to its board governance structure alongside its quarterly financial results. The $16 billion market cap biopharmaceutical company, which closed at $251.58 per share, amended its Non-Employee Director Compensation Policy for the sixteenth time since its original adoption in May 2013 (10-Q filing, 2026-08-03).
The most recent amendment to the compensation policy, approved by the board on April 23, 2026, maintains the existing framework under which non-employee directors receive a base cash retainer of $75,000 annually (10-Q filing, 2026-08-03). Additional compensation varies by role, with the board chairperson eligible for an extra $100,000 per year, while the lead independent director receives $50,000 in supplemental compensation (10-Q filing, 2026-08-03).
Equity Compensation Structure
Under the revised policy, non-employee directors continue to receive annual restricted stock unit (RSU) awards with a grant date value of approximately $400,000, granted under the company's Amended and Restated 2007 Non-Employee Directors Stock Award Plan (10-Q filing, 2026-08-03). These awards vest in full on the first anniversary of the annual general meeting in the year of grant, subject to continued service (10-Q filing, 2026-08-03).
The policy caps total compensation for non-employee directors at $750,000 per annual period, or $1,350,000 for directors first appointed during that period, with equity awards valued at grant date fair value for financial reporting purposes (10-Q filing, 2026-08-03).
Controls and Risk Disclosures
In its quarterly filing, Jazz Pharmaceuticals' principal executive officer and principal financial officer concluded that the company's disclosure controls and procedures were effective as of June 30, 2026 (10-Q filing, 2026-08-03). Management reported no changes to internal control over financial reporting during the second quarter that materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting (10-Q filing, 2026-08-03).
The company also disclosed that there were no material changes to its market risk profile during the six months ended June 30, 2026, compared to disclosures in its 2025 Annual Report on Form 10-K (10-Q filing, 2026-08-03).
Insider Activity Context
According to MarginX data, recent insider transactions at Jazz Pharmaceuticals include a sale of 6,000 shares by director Bruce C. Cozadd, while executives Samantha Pearce and Renee D. Gala had shares withheld for tax purposes totaling 2,527 and 4,835 shares, respectively.
The filing comes as investors await the Federal Reserve's September 16 rate decision, which will include updated economic projections, followed by another FOMC decision on October 28, per MarginX data.
Jazz Pharmaceuticals, headquartered in Ireland, develops and commercializes medicines for serious diseases including sleep disorders and oncology conditions. The company's frequent amendments to its director compensation policy reflect ongoing governance adjustments as the organization has evolved over the past thirteen years.
This article was generated by MarginX from the 10-Q filing on 2026-08-03. It is not investment advice.